Literature DB >> 32859710

Deep-Learning Generation of Synthetic Intermediate Projections Improves 177Lu SPECT Images Reconstructed with Sparsely Acquired Projections.

Tobias Rydén1, Martijn Van Essen2, Ida Marin1, Johanna Svensson3, Peter Bernhardt4,5.   

Abstract

The aims of this study were to decrease the 177Lu-SPECT acquisition time by reducing the number of projections and to circumvent image degradation by adding deep-learning-generated synthesized projections.
Methods: We constructed a deep convolutional U-net-shaped neural network for generation of synthetic intermediate projections (CUSIPs). The number of SPECT investigations was 352 for training, 37 for validation, and 15 for testing. The input was every fourth projection of 120 acquired SPECT projections, that is, 30 projections. The output was 30 synthetic intermediate projections (SIPs) per CUSIP. SPECT images were reconstructed with 120 or 30 projections, or with 120 projections when 90 SIPs were generated from 30 projections (30-120SIPs), using 3 CUSIPs. The reconstructions were performed with 2 ordered-subset expectation maximization (OSEM) algorithms: attenuation-corrected (AC) OSEM, and attenuation, scatter, and collimator response-corrected (ASCC) OSEM. The quality of the SIPs and SPECT images was quantitatively evaluated with root-mean-square error, peak signal-to-noise ratio (PSNR), and structural similarity (SSIM) index metrics. From a Jaszczak SPECT phantom, the recovery and signal-to-noise ratio (SNR) were determined. In addition, an experienced observer qualitatively assessed the SPECT image quality of the test set. Kidney activity concentrations, as determined from the different SPECT images, were compared.
Results: The generated SIPs had a mean SSIM value of 0.926 (SD, 0.061). For AC-OSEM, the reconstruction with 30-120SIPs had higher SSIM (0.993 vs. 0.989, P < 0.001) and PSNR (49.5 vs. 47.2, P < 0.001) values than the reconstruction with 30 projections. ASCC-OSEM had higher SSIM and PSNR values than AC-OSEM (P < 0.001). There was a minor loss in recovery for 30-120SIPs, but SNR was clearly improved compared with 30 projections. The observer assessed 27 of 30 images reconstructed with 30 projections as having unacceptable noise levels, whereas the corresponding values were 2 of 60 for 30-120SIPs and 120 projections. Image quality did not differ significantly between 30-120SIPs and 120 projections. The kidney activity concentration was similar between the different projection sets, excepting a minor reduction of 2.5% for ASCC-OSEM 30-120SIPs.
Conclusion: Adopting SIPs for sparsely acquired projections considerably recovers image quality and could allow a reduced SPECT acquisition time in clinical dosimetry protocols.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  177Lu; SPECT; deep-learning; dosimetry

Year:  2020        PMID: 32859710      PMCID: PMC8049368          DOI: 10.2967/jnumed.120.245548

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

1.  MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.

Authors:  Michael Ljungberg; Anna Celler; Mark W Konijnenberg; Keith F Eckerman; Yuni K Dewaraja; Katarina Sjögreen-Gleisner; Wesley E Bolch; A Bertrand Brill; Frederic Fahey; Darrell R Fisher; Robert Hobbs; Roger W Howell; Ruby F Meredith; George Sgouros; Pat Zanzonico; Klaus Bacher; Carlo Chiesa; Glenn Flux; Michael Lassmann; Lidia Strigari; Stephan Walrand
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

2.  Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

Authors:  Andreas Delker; Wolfgang Peter Fendler; Clemens Kratochwil; Anika Brunegraf; Astrid Gosewisch; Franz Josef Gildehaus; Stefan Tritschler; Christian Georg Stief; Klaus Kopka; Uwe Haberkorn; Peter Bartenstein; Guido Böning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-29       Impact factor: 9.236

3.  177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

Authors:  Michael Garkavij; Mattias Nickel; Katarina Sjögreen-Gleisner; Michael Ljungberg; Tomas Ohlsson; Karin Wingårdh; Sven-Erik Strand; Jan Tennvall
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

4.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

5.  Monte Carlo-based SPECT reconstruction within the SIMIND framework.

Authors:  Johan Gustafsson; Gustav Brolin; Michael Ljungberg
Journal:  Phys Med Biol       Date:  2018-12-12       Impact factor: 3.609

6.  Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.

Authors:  John Violet; Price Jackson; Justin Ferdinandus; Shahneen Sandhu; Tim Akhurst; Amir Iravani; Grace Kong; Aravind Ravi Kumar; Sue Ping Thang; Peter Eu; Mark Scalzo; Declan Murphy; Scott Williams; Rodney J Hicks; Michael S Hofman
Journal:  J Nucl Med       Date:  2018-10-05       Impact factor: 10.057

7.  Synthesis of Patient-Specific Transmission Data for PET Attenuation Correction for PET/MRI Neuroimaging Using a Convolutional Neural Network.

Authors:  Karl D Spuhler; John Gardus; Yi Gao; Christine DeLorenzo; Ramin Parsey; Chuan Huang
Journal:  J Nucl Med       Date:  2018-08-30       Impact factor: 10.057

8.  Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate.

Authors:  Mattias Sandström; Ulrike Garske; Dan Granberg; Anders Sundin; Hans Lundqvist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-02       Impact factor: 9.236

9.  Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.

Authors:  Anna Sundlöv; Katarina Sjögreen-Gleisner; Johanna Svensson; Michael Ljungberg; Tomas Olsson; Peter Bernhardt; Jan Tennvall
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-22       Impact factor: 9.236

10.  Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases.

Authors:  Linn Hagmarker; Johanna Svensson; Tobias Rydén; Martijn van Essen; Anna Sundlöv; Katarina Sjögreen Gleisner; Peter Gjertsson; Peter Bernhardt
Journal:  J Nucl Med       Date:  2019-03-22       Impact factor: 10.057

View more
  3 in total

1.  Analysis of a deep learning-based method for generation of SPECT projections based on a large Monte Carlo simulated dataset.

Authors:  Julian Leube; Johan Gustafsson; Michael Lassmann; Maikol Salas-Ramirez; Johannes Tran-Gia
Journal:  EJNMMI Phys       Date:  2022-07-19

Review 2.  Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics.

Authors:  Virginia Liberini; Riccardo Laudicella; Michele Balma; Daniele G Nicolotti; Ambra Buschiazzo; Serena Grimaldi; Leda Lorenzon; Andrea Bianchi; Simona Peano; Tommaso Vincenzo Bartolotta; Mohsen Farsad; Sergio Baldari; Irene A Burger; Martin W Huellner; Alberto Papaleo; Désirée Deandreis
Journal:  Eur Radiol Exp       Date:  2022-06-15

3.  EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands.

Authors:  Katarina Sjögreen Gleisner; Nicolas Chouin; Pablo Minguez Gabina; Francesco Cicone; Silvano Gnesin; Caroline Stokke; Mark Konijnenberg; Marta Cremonesi; Frederik A Verburg; Peter Bernhardt; Uta Eberlein; Jonathan Gear
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-14       Impact factor: 10.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.